5
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Peritonitis Rates in CAPD Patients Using the UVXD and O-Set Systems

, , &
Pages 225-230 | Published online: 07 Jul 2009
 

Abstract

We report experience with O-set and UVXD systems. Sixty-nine O-set patients (34 male; mean age ± SD = 45.7 ± 13.2 years) were compared with 54 UVXD patients (27 male; 56.8 ± 16.8 years). Total (mean ± SD) experiences were 974 (14.1 ± 10.8) months on O-set and 1010.9 (18.7 ± 15.7) months on UVXD. Thirty-two O-set patients avoided peritonitis; 37 had 91 episodes. Seventeen UVXD patients avoided peritonitis; 37 had 137 episodes. Peritonitis occurred each 10.7 months (O-set) versus 7.4 months (UVXD), which was significantly different (p = 0.032, Z test; 95% confidence interval = -0.142 to + 0.226). There were 18 relapses in 9 O-set patients, 34 in 12 UVXD. Gram-positive organisms caused 58.2% and 66%; gram-negative, 13.2% and 8.8%; and culture negative, 24.2% and 23.4% of peritonitis in O-set and UVXD, respectively. The time to first peritonitis was not different, 7.4 ± 6.6 months O-set and 7.2 ± 7.9 months (UVXD). There was no difference in the peritonitis-free period, 13.0 ± 10.0 months (O-set) and 16.5 ± 14.3 months (UVXD). There were 1.12 (O-set) and 16.1 (UVXD) cases per patient year, and 10.7 (O-set) and 7.43 (UVXD) patient months per episode. The peritonitis rate odds ratio was 1:1.85 (O-set.UVXD).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.